The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Exclusion Criteria

• •Prior treatment with EGFR TKI
• •Patients who required dose reduction of gefitinib
• •Surgery undertaken less than 4 weeks before the study
• •Localized radiotherapy unless completed more than 2 weeks before the study
• •Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or arrhythmia
• •Pregnant or nursing women ( Women of reproductive potential have to agree to use an effective contraceptive method (hormonal or barrier methods))
• •Uncontrolled symptomatic brain metastasis
• •Prior history of malignancy within 5 years from study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, well-treated thyroid cancer
• •Concomitant use of CYP3A4 inducers/inhibitors
• •Prolonged QT interval in ECG (QTc \>450 msec)
• •Patients who cannot take a medicine orally or who have a gastrointestinal absorption disorder